Based on the opinions of our employees, we’re a 2022 World Class Workplace. This label is awarded by Effectory to celebrate organizations who are dedicated to their people. Thanks to everyone at Merus who makes our organization a great place to work.
#CloseInOnCancer
We look forward to sharing robust updated interim phase 2 data on petosemtamab plus pembrolizumab as first line treatment for PD-L1+ r/m #HNSCC, on the entire 45 patient data set, on an upcoming investor conference call on May 22 at 5:30 p.m. ET and in our presentation at #ASCO25. We continue to believe petosemtamab has the potential to be a first and best in class, practice-changing medicine for the treatment of r/m #HNSCC. #CloseInOnCancer
https://t.co/rKqhVaCDmq
In May 2024 and February 2025, the U.S. FDA granted Breakthrough Therapy designations to petosemtamab: as monotherapy in 2L+ r/m #HNSCC, and in combination with pembrolizumab in 1L PD-L1+ r/m #HNSCC, respectively. We are dedicated to advancing petosemtamab as a potential new therapy for the treatment of r/m #HNSCC.
#ClosingInOnCancer
Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN2 trial has over 93 sites open across North and South America, Europe, Asia, and Australia. For more information,
visit https://t.co/oCRXQ6YCno
NCT06496178. #CloseInOnCancer
Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN1 trial has over 105 sites open across North and South America, Europe, Asia, and Australia. For more information,
visit https://t.co/oCRXQ6YCno
NCT06525220. #CloseInOnCancer
At Merus, every day, we bring a sense of urgency and a passion to help patients. In April we recognize the patients with recurrent/metastatic #HNSCC. We remain steadfast in our commitment to advance our lead cancer drug candidate petosemtamab as a potential new treatment for patients.
#CloseInOnCancer
Bill Lundberg, MD, Merus’ CEO, will present today at Citi’s 2025 Virtual Oncology Leadership Summit. The presentation will be available on our Investors page and for a limited time thereafter.
#CloseInOnCancer
We hope to see you at #ESMOAsia24 where clinical trial data on petosemtamab as 2L+ treatment of recurrent/metastatic #HNSCC will be presented.
#ClosingInOnCancer
https://t.co/f9rkn4Un5J
Attending AMP2024? Visit us at Booth 706. Did you know that NRG1+ tumors may have a higher rate of metastasis compared with KRAS+ tumors? Go to https://t.co/tOIPV4rLsR and find out more about the metastatic potential of NRG1+ tumors. #AMP2024#PrecisionOncology#FindTheFusions #PrecisionMedicine
Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat today at the Stifel 2024 Healthcare Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer
Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer
The Merus team recently celebrated the end of summer and welcomed the start of the fall season with a fun and highly competitive outing.
#Team#CloseInOnCancer
Please join us in welcoming Audrey as our Chief People Officer. Audrey has more than 25 years of experience attracting, developing, and retaining top talent in the pharmaceutical and biotechnology industries. We're excited to have her on the team as we #CloseInOnCancer.
What is the optimal way to detect pathogenic gene fusions like NRG1? Benjamin Weinberg, MD, highlights the advantages of RNA-based next generation sequencing and how it can capture what other tests might miss. Watch the video at https://t.co/GRKKqHO7IV #PrecisionOncology #FindTheFusions #PrecisionMedicine
Over the summer, we profiled some of our team members. You can find their stories, along with our current vacancies on our careers page: https://t.co/dptxvhM0Lf
#CloseInOnCancer#JoinTheMerusMission
We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab 1L r/m #HNSCC#CloseInOnCancer
We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab in 1L PD-L1+ r/m #HNSCC#CloseInOnCancer
https://t.co/Bg9P31qOqU